AIDS
MCID: ACQ007
MIFTS: 60

Acquired Immunodeficiency Syndrome (AIDS) malady

Categories: Infectious diseases, Immune diseases

Aliases & Classifications for Acquired Immunodeficiency Syndrome

Aliases & Descriptions for Acquired Immunodeficiency Syndrome:

Name: Acquired Immunodeficiency Syndrome 12 3 42 14 69
Acquired Immune Deficiency Syndrome 12 3 14
Aids 12 45
Acquired Immune Deficiency 12

Classifications:



External Ids:

Disease Ontology 12 DOID:635
ICD10 33 B20
MeSH 42 D000163
NCIt 47 C2851
UMLS 69 C0001175

Summaries for Acquired Immunodeficiency Syndrome

Disease Ontology : 12 A Human immunodeficiency virus infectious disease that results_in reduction in the numbers of CD4-bearing helper T cells below 200 per µL of blood or 14% of all lymphocytes thereby rendering the subject highly vulnerable to life-threatening infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted_by sexual contact, transmitted_by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted_by congenital method, and transmitted_by contaminated needles. Opportunistic infections are common in people with AIDS.

MalaCards based summary : Acquired Immunodeficiency Syndrome, also known as acquired immune deficiency syndrome, is related to hepatitis and cryptococcosis. An important gene associated with Acquired Immunodeficiency Syndrome is CCR5 (C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ethanol and Mannitol have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and brain, and related phenotypes are cellular and homeostasis/metabolism

CDC : 3 Help

Related Diseases for Acquired Immunodeficiency Syndrome

Diseases related to Acquired Immunodeficiency Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 642)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.2 IFNG IL10 IL2 IL6 TNF
2 cryptococcosis 30.2 CD4 CD40LG IL10 TNF
3 syphilis 30.1 CD4 CD40LG CD79A
4 uveitis 30.0 CD4 CD40LG CD79A TNF
5 tuberculosis 29.9 CD4 CD40LG IL10 IL1B IL2 IL6
6 central nervous system lymphoma 29.8 IL10 IL1B IL6 TNF
7 tracheitis 29.8 CD79A IFNG IL2 TNF
8 choroiditis 29.8 ALB IL10 IL1B IL6 TNF
9 neuropathy 29.7 IL1B IL6 TNF
10 drug dependence 29.7 IFNA1 IL6 TNF
11 dermatitis herpetiformis 29.6 CD4 CD40LG TNF
12 intussusception 29.6 IL1B TNF
13 abdominal tuberculosis 29.6 CD4 CD40LG CD79A IL10
14 dengue hemorrhagic fever 29.6 IFNG IL10 IL2 TNF
15 rosacea 29.5 ALB IFNG IL10 IL1B
16 cataract 29.5 ALB CSF2 IL1B TNF
17 histiocytosis 29.4 CD79A IL1B IL6 TNF
18 tinea capitis 29.4 IL1B IL2 IL6 TNF
19 chorioretinitis 29.4 CD40LG IFNG IL10 TNF
20 pyoderma gangrenosum 29.4 CSF2 IFNG IL1B IL6 TNF
21 nasopharyngitis 29.2 CD79A IFNG IL1B IL2 IL6 TNF
22 membranoproliferative glomerulonephritis 28.7 ALB CCR5 CD4 CD40LG CD79A CSF2
23 rheumatoid arthritis 28.3 CCL3 CCR2 CD40LG CD79A CSF2 IFNG
24 hiv-1 11.6
25 primary central nervous system lymphoma 11.1
26 efavirenz, poor metabolism of 10.8
27 oral hairy leukoplakia 10.8
28 lymphoma 10.5
29 46 xy gonadal dysgenesis 10.4 B2M CD4 CD79A
30 atopic dermatitis 6 10.4 ALB CD79A
31 retinitis 10.4
32 congenital nystagmus 10.4 ALB B2M CD79A
33 elephantiasis 10.4 CD4 IFNG IL10
34 ovarian papillary cystadenoma 10.3 ALB CD4 IFNG
35 lepromatous leprosy 10.3 IFNG IL10 IL6
36 multiple mitochondrial dysfunctions syndrome 10.3 IFNG IL10 IL6
37 immune-complex glomerulonephritis 10.3 CD79A IFNG IL6
38 malignant hyperthermia susceptibility 1 10.3 ALB B2M CD79A
39 acute allergic sanguinous otitis media 10.3 B2M IL2 IL6
40 pyridoxal 5'-phosphate-dependent epilepsy 10.3 IL10 TNF
41 congenital dyserythropoietic anemia 10.3 ALB TNF
42 non-gestational choriocarcinoma 10.3 ALB IFNG IL10
43 aniseikonia 10.3 CSF2 IFNG TNF
44 fallopian tube serous adenocarcinoma 10.3 ALB IL10 IL6
45 hemiplegia 10.3 ALB CD79A IL10
46 usher syndrome, type 2a 10.3 IFNG IL10 IL6
47 chronic gonococcal salpingitis 10.3 ALB CSF2 IL2
48 loiasis 10.3 CD79A IFNG IL10
49 glucose intolerance 10.3 B2M IFNG TNF
50 prostate carcinoma in situ 10.3 CD4 CD40LG

Graphical network of the top 20 diseases related to Acquired Immunodeficiency Syndrome:



Diseases related to Acquired Immunodeficiency Syndrome

Symptoms & Phenotypes for Acquired Immunodeficiency Syndrome

MGI Mouse Phenotypes related to Acquired Immunodeficiency Syndrome:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 IL2 IL6 ITIH4 MYC TNF ALB
2 homeostasis/metabolism MP:0005376 10.41 ALB B2M CCR2 CCR5 CD38 CD4
3 hematopoietic system MP:0005397 10.4 TNF B2M CCR2 CCR5 CD38 CD4
4 cardiovascular system MP:0005385 10.36 B2M CCR2 CCR5 CD40LG CSF2 F9
5 immune system MP:0005387 10.36 IL6 MYC TNF B2M CCR2 CCR5
6 endocrine/exocrine gland MP:0005379 10.29 TNF ALB B2M CD38 CD4 CD40LG
7 digestive/alimentary MP:0005381 10.26 IL10 IL2 IL6 MYC TNF ALB
8 mortality/aging MP:0010768 10.24 TNF ALB B2M CCR2 CCR5 CD4
9 liver/biliary system MP:0005370 10.22 ALB B2M CCR2 CCR5 CD79A F9
10 neoplasm MP:0002006 10.17 TNF ALB B2M CCR2 CCR5 CD79A
11 integument MP:0010771 10.13 B2M CD4 CD40LG CSF2 IFNG IL10
12 nervous system MP:0003631 10.07 B2M CCR2 CCR5 CD4 CD40LG CD79A
13 no phenotypic analysis MP:0003012 9.81 CCR2 CCR5 CD4 CD79A IFNG IL10
14 reproductive system MP:0005389 9.65 MYC TNF B2M CCR5 CD40LG CSF2
15 skeleton MP:0005390 9.28 CCR2 CD40LG CSF2 IFNG IL10 IL1B

Drugs & Therapeutics for Acquired Immunodeficiency Syndrome

Drugs for Acquired Immunodeficiency Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 894)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
2
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2 69-65-8 453 6251
3
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
5
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 561-27-3 5462328
6
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1 54-11-5 942 89594
7
Fenofibrate Approved Phase 4,Phase 3,Phase 2 49562-28-9 3339
8
Ezetimibe Approved Phase 4 163222-33-1 150311
9
Pravastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 81093-37-0 54687
10
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
11
Zinc Approved Phase 4,Phase 3,Phase 1,Phase 2 7440-66-6 32051 23994
12
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
13
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
14
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 155213-67-5 392622
15
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 1 147-94-4 6253
16
Indinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 150378-17-9 5362440
17
Amprenavir Approved Phase 4,Phase 2,Phase 3,Phase 1 161814-49-9 65016
18
Nelfinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 159989-64-7 64143
19
Methotrexate Approved Phase 4,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
20
Rifampin Approved Phase 4,Phase 3,Phase 2,Phase 1 13292-46-1 5458213 5381226
21
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 192725-17-0 92727
22
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 154598-52-4 64139
23
Nevirapine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 129618-40-2 4463
24
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
25
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 30516-87-1 35370
26
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1 24280-93-1 446541
27
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147127-20-6 464205
28
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1 128794-94-5 5281078
29
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 134678-17-4 60825
30
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
31
Candesartan Approved Phase 4 139481-59-7 2541
32
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
33
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1 69655-05-6 50599
34
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1 36791-04-5 37542
35
Fluconazole Approved Phase 4,Phase 3,Phase 2,Phase 1 86386-73-4 3365
36
rituximab Approved Phase 4,Phase 2,Phase 1 174722-31-7 10201696
37
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3056-17-5 18283
38
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Phase 1 6493-05-6 4740
39
Bleomycin Approved Phase 4,Phase 3,Phase 2 11056-06-7 5360373
40
Zoledronic acid Approved Phase 4,Phase 2 118072-93-8 68740
41
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 136470-78-5 65140 441300
42
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
43
Isoniazid Approved Phase 4,Phase 3,Phase 2,Phase 1 54-85-3 3767
44
Pyrazinamide Approved Phase 4,Phase 3,Phase 2,Phase 1 98-96-4 1046
45
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 376348-65-1 3002977
46
Enfuvirtide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159519-65-0 16130199
47
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
48
Praziquantel Approved, Vet_approved Phase 4 55268-74-1 4891
49
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 2,Phase 1 723-46-6 5329
50
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1 443-48-1 4173

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
2 Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults Unknown status NCT01811823 Phase 4
3 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4
4 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
5 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4
6 Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4
7 Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects Unknown status NCT00740064 Phase 4
8 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4
9 Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4
10 PI Vs. NNRTI Based Therapy for HIV Advanced Disease Unknown status NCT00162643 Phase 4
11 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4
12 Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients Unknown status NCT01059422 Phase 4
13 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4
14 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4
15 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4
16 Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya Unknown status NCT01015989 Phase 4
17 Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Unknown status NCT01875952 Phase 4
18 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4
19 Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients Unknown status NCT01013987 Phase 4
20 A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients Unknown status NCT00199121 Phase 4
21 Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4
22 Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy Unknown status NCT01049685 Phase 4
23 Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs Unknown status NCT00005000 Phase 4
24 Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status NCT00011895 Phase 4
25 Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Unknown status NCT01230580 Phase 4
26 Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts Unknown status NCT01928407 Phase 4
27 Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment Unknown status NCT00005017 Phase 4
28 Early Antiviral Therapy for Critically Ill HIV Infected Patients Unknown status NCT01455688 Phase 4
29 BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects Unknown status NCT00388492 Phase 4
30 Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection Unknown status NCT01343225 Phase 4
31 Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4
32 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4
33 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4
34 Once Daily 3TC, Efavirenz and ddI for HIV Infection Unknown status NCT00214435 Phase 4
35 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4
36 Does Rosuvastatin Delay Progression of Atherosclerosis in HIV Unknown status NCT01813357 Phase 4
37 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
38 The Self-Collection Study: a Study of Self-collected HPV Testing and Results Counseling Unknown status NCT01843478 Phase 4
39 PrEP Demonstration Project (PRELUDE Study) Unknown status NCT02206555 Phase 4
40 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Unknown status NCT00843661 Phase 4
41 Simplification From Protease Inhibitors to Raltegravir Unknown status NCT00941083 Phase 4
42 Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children Unknown status NCT00604617 Phase 4
43 RAltegravir Switch STudy: Effects on Endothelial Recovery Unknown status NCT01453933 Phase 4
44 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4
45 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4
46 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism Unknown status NCT00759070 Phase 4
47 Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment Unknown status NCT00751153 Phase 4
48 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4
49 A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients. Unknown status NCT01736761 Phase 4
50 Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand Unknown status NCT01538940 Phase 4

Search NIH Clinical Center for Acquired Immunodeficiency Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: acquired immunodeficiency syndrome

Genetic Tests for Acquired Immunodeficiency Syndrome

Anatomical Context for Acquired Immunodeficiency Syndrome

MalaCards organs/tissues related to Acquired Immunodeficiency Syndrome:

39
T Cells, Breast, Brain, Bone, B Cells, Thyroid, Skin

Publications for Acquired Immunodeficiency Syndrome

Articles related to Acquired Immunodeficiency Syndrome:

(show top 50) (show all 960)
id Title Authors Year
1
Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome After Initiating Antiretroviral Therapy. ( 27984023 )
2017
2
Human immunodeficiency virus (HIV) is highly associated with giant idiopathic esophageal ulcers in acquired immunodeficiency syndrome (AIDS) patients. ( 27830031 )
2016
3
Study of infections among human immunodeficiency virus/acquired immunodeficiency syndrome patients in Shadan Hospital, Telangana, India. ( 27890948 )
2016
4
Hepatic Kaposi Sarcoma Revisited: An Important but Less Commonly Seen Neoplasm in Patients With Acquired Immunodeficiency Syndrome. ( 27984514 )
2016
5
Pathologic lesions in children with acquired immunodeficiency syndrome an autopsy study of 11 cases from Mumbai, India. ( 27166033 )
2016
6
Oral manifestations of human immunodeficiency virus/acquired immunodeficiency syndrome and their correlation to cluster of differentiation lymphocyte count in population of North-East India in highly active antiretroviral therapy era. ( 27994425 )
2016
7
Analysis and Outcomes of Cataract Surgery in Patients with Acquired Immunodeficiency Syndrome. ( 27082491 )
2016
8
Miliary tuberculosis and acquired immunodeficiency syndrome - 'a cursed duet'. ( 27802849 )
2016
9
Pathology of thyroid in acquired immunodeficiency syndrome. ( 27510660 )
2016
10
Autoimmunity and dysmetabolism of human acquired immunodeficiency syndrome. ( 26676359 )
2016
11
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in Older Adults. ( 27394024 )
2016
12
Toxoplasmic encephalitis: role of Human Leucocyte Antigens/alleles associated with rapid progression to Acquired Immunodeficiency Syndrome. ( 26786385 )
2016
13
De Novo intracerebral aneurysm in a child with acquired immunodeficiency syndrome. ( 26818175 )
2016
14
Recursion-based depletion of human immunodeficiency virus-specific naive CD4(+) T cells may facilitate persistent viral replication and chronic viraemia leading to acquired immunodeficiency syndrome. ( 27515208 )
2016
15
Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome. ( 26962942 )
2016
16
Erratum to cardiac obstruction secondary to metastatic invasion - A rare complication of Human Herpes Virus 8-positive plasmablastic lymphoma in acquired immunodeficiency syndrome. ( 27867656 )
2016
17
Prevalence of Malnutrition and Associated Factors among Hospitalized Patients with Acquired Immunodeficiency Syndrome in Jimma University Specialized Hospital, Ethiopia. ( 27358542 )
2016
18
Skin aging in patients with acquired immunodeficiency syndrome. ( 27649952 )
2016
19
Cryptococcosis in Acquired Immunodeficiency Syndrome Patients Clinically Confirmed and/or Diagnosed at Necropsy in a Teaching Hospital in Brazil. ( 27458037 )
2016
20
Food Security in Households of People Living With Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: A Cross-sectional Study in a Subdivision of Darjeeling District, West Bengal. ( 27499166 )
2016
21
First report of Cystoisospora belli parasitemia in a patient with acquired immunodeficiency syndrome. ( 26751889 )
2016
22
Opportunistic Neurologic Infections in Patients with Acquired Immunodeficiency Syndrome (AIDS). ( 26747443 )
2016
23
Central Nervous System Histoplasmosis in Acquired Immunodeficiency Syndrome. ( 26897273 )
2016
24
Multiple coronary aneurysms in a young adult with acquired immunodeficiency syndrome. ( 27168940 )
2016
25
The First Case of Vestibulocochlear Neuritis in a Patient with Acquired Immunodeficiency Syndrome in Korea. ( 27433384 )
2016
26
Computer simulations of the interaction of human immunodeficiency virus (HIV) aspartic protease with spherical gold nanoparticles: implications in acquired immunodeficiency syndrome (AIDS). ( 27483476 )
2016
27
Frosted branch angiitis in acquired immunodeficiency syndrome patients with cytomegalovirus retinitis. ( 27640360 )
2016
28
Prostatic abscess caused by Mycobacterium tuberculosis and Escherichia coli in a patient with acquired immunodeficiency syndrome. ( 26230573 )
2015
29
Prevalence of Intermediate-Stage Age-Related Macular Degeneration in Patients With Acquired Immunodeficiency Syndrome. ( 25769246 )
2015
30
Ocular Manifestations of Acquired Immunodeficiency Syndrome. ( 26240508 )
2015
31
The clinical characteristics of 80 cases of acquired immunodeficiency syndrome-associated Kaposi's sarcoma in Xinjiang Autonomous Region and the effect of different treatments on the prognosis. ( 26770484 )
2015
32
Prevalence and Predictors of Thyroid Dysfunction in Patients with HIV Infection and Acquired Immunodeficiency Syndrome: An Indian Perspective. ( 26798547 )
2015
33
Characteristics relating to the interiorization of acquired immunodeficiency syndrome in Brazil: a cross-sectional study. ( 26284512 )
2015
34
A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome. ( 26140474 )
2015
35
Successful recovery of MERS CoV pneumonia in a patient with acquired immunodeficiency syndrome: a case report. ( 25542475 )
2015
36
Longitudinal Melanonychia in an African Patient with Acquired Immunodeficiency Syndrome (AIDS). ( 26137665 )
2015
37
Spinal cord toxoplasmosis in human immunodeficiency virus infection/acquired immunodeficiency syndrome. ( 25835092 )
2015
38
Features of Acquired Immunodeficiency Syndrome-related Lymphoma on (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. ( 26564515 )
2015
39
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Risk (HIV/AIDS)-Taking Behavior and HIV/AIDS Knowledge With African-American Women. ( 26870711 )
2015
40
Retrospective study of cytomegalovirus retinitis complicated with acquired immunodeficiency syndrome. ( 26309620 )
2015
41
An Aggressive Plasmablastic Lymphoma of the Oral Cavity as Primary Manifestation of Acquired Immunodeficiency Syndrome: Case Report and Literature Review. ( 26491484 )
2015
42
Progressive outer retinal necrosis associated with occlusive vasculitis in acquired immunodeficiency syndrome. ( 26002429 )
2015
43
A Clinical Study of Acquired Immunodeficiency Syndrome Associated Penicillium Marneffei Infection from a Non-Endemic Area in China. ( 26083736 )
2015
44
Co-infections with Ureaplasma parvum and Herpes simplex virus in an acquired immunodeficiency syndrome patient. ( 26392670 )
2015
45
A case of acquired immunodeficiency syndrome with ileocecal ulcer. ( 26440687 )
2015
46
Retinal structural features of cytomegalovirus retinitis with acquired immunodeficiency syndrome: an adaptive optics imaging and optical coherence tomography study. ( 26148637 )
2015
47
De Novo intracerebral aneurysm in a child with acquired immunodeficiency syndrome. ( 26166600 )
2015
48
Public perceptions about HIV/AIDS and discriminatory attitudes toward people living with acquired immunodeficiency syndrome in Iran. ( 26726933 )
2015
49
Rapid Tests and the Diagnosis of Visceral Leishmaniasis and Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Coinfection. ( 26416105 )
2015
50
Toxoplasmosis of spinal cord in acquired immunodeficiency syndrome patient presenting as paraparesis: a rare entity. ( 25538456 )
2014

Variations for Acquired Immunodeficiency Syndrome

Expression for Acquired Immunodeficiency Syndrome

Search GEO for disease gene expression data for Acquired Immunodeficiency Syndrome.

Pathways for Acquired Immunodeficiency Syndrome

Pathways related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.14 B2M CCL3 CCR2 CCR5 CD4 CD40LG
2
Show member pathways
13.96 CCL3 CCR2 CCR5 CD4 CD40LG CSF2
3
Show member pathways
13.76 CCL3 CCR2 CCR5 CD4 CD40LG CSF2
4
Show member pathways
13.65 CCL3 CD4 IFNA1 IFNG IL10 IL1B
5
Show member pathways
13.54 CCL3 CCR2 CCR5 CD4 CD40LG CSF2
6
Show member pathways
13.44 CCL3 CCR2 CCR5 CD4 CD40LG CSF2
7
Show member pathways
13.35 B2M CCL3 CCR2 CCR5 CD4 CD40LG
8
Show member pathways
13.07 CCL3 IFNA1 IFNG IL10 IL1B IL2
9
Show member pathways
12.98 B2M CD4 CD40LG IFNA1 IFNG IL10
10
Show member pathways
12.9 IFNA1 IFNG IL1B IL2 IL6 TNF
11
Show member pathways
12.79 IFNA1 IFNG IL1B IL6 TNF
12
Show member pathways
12.78 CCR5 CD4 CD40LG IFNG IL1B TNF
13
Show member pathways
12.78 CD4 CD40LG CD79A IFNG IL10 IL2
14
Show member pathways
12.77 CD4 IFNG IL10 IL1B IL2 IL6
15
Show member pathways
12.76 CD40LG IL1B IL2 IL6 TNF
16
Show member pathways
12.76 CD4 IFNG IL10 IL1B IL2 IL6
17
Show member pathways
12.61 CSF2 IFNA1 IFNG IL2 TNF
18 12.56 B2M CCR2 CD38 CD40LG CD79A IFNA1
19 12.54 CSF2 IL2 IL6 MYC TNF
20
Show member pathways
12.51 CCR5 CD4 CD40LG CSF2 IFNG IL10
21
Show member pathways
12.49 ALB IFNG IL1B IL2 IL6 TNF
22
Show member pathways
12.45 CSF2 IFNG IL1B IL6 TNF
23
Show member pathways
12.41 CCR5 CD40LG IFNG IL10 IL1B TNF
24 12.39 IFNA1 IFNG IL10 IL1B IL6 TNF
25
Show member pathways
12.37 CSF2 IFNA1 IFNG IL10 IL2 IL6
26 12.36 CD38 IFNG IL10 MYC
27
Show member pathways
12.34 IFNG IL1B IL6 TNF
28
Show member pathways
12.32 IFNA1 IFNG IL10 IL1B IL2 IL6
29
Show member pathways
12.26 IFNG IL1B IL6 TNF
30 12.26 IFNG IL6 MYC TNF
31 12.25 IL10 IL1B IL6 TNF
32 12.18 CCR2 IFNG IL1B IL2 IL6 MYC
33 12.14 IL10 IL1B IL6 MYC TNF
34
Show member pathways
12.14 B2M CCL3 CCR5 CD4 IFNG IL1B
35 12.09 CD38 CD4 CSF2 IL1B IL6 TNF
36 12.08 CSF2 IFNG IL10 IL1B IL6 TNF
37
Show member pathways
12.08 CD4 IFNG IL10 IL1B IL2 IL6
38 12.06 CSF2 IL1B IL6 TNF
39 12.05 CCL3 IFNG IL1B IL6
40 12.04 CCL3 CSF2 IFNG IL1B IL6 TNF
41
Show member pathways
12.03 CD4 IFNG IL1B IL6
42 12 CCL3 CSF2 IFNG IL1B IL6
43 11.98 CD38 CD4 CD79A CSF2 IFNG IL10
44
Show member pathways
11.94 CD40LG CSF2 IFNG IL2 TNF
45 11.93 CSF2 IFNG IL2 IL6
46 11.9 CCL3 CD4 IFNG IL10 IL1B IL2
47 11.89 IL10 IL1B IL6 TNF
48 11.87 IFNA1 IFNG IL10 IL2 IL6
49 11.85 CD40LG IL10 IL6 TNF
50 11.85 CCL3 CCR2 CSF2 IL1B IL6 TNF

GO Terms for Acquired Immunodeficiency Syndrome

Cellular components related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.8 B2M CCR5 CD38 CD4 CD40LG TNF
2 endoplasmic reticulum lumen GO:0005788 9.65 ALB B2M CD4 F9 IL6
3 external side of plasma membrane GO:0009897 9.56 B2M CCR5 CD4 CD40LG CD79A IFNG
4 extracellular space GO:0005615 9.44 ALB B2M CCL3 CD40LG CSF2 F9
5 extracellular region GO:0005576 10 ALB B2M CCL3 CD40LG CSF2 F9

Biological processes related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
id Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.98 CCR2 IFNA1 IL1B IL6
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.97 CCR2 CCR5 CD38 IL2
3 positive regulation of protein phosphorylation GO:0001934 9.97 CD4 IFNG IL1B IL2 TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 CD40LG IL1B IL6 TNF
5 positive regulation of gene expression GO:0010628 9.95 CCL3 CSF2 IFNG IL1B IL6 MYC
6 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.93 IL10 IL1B IL6 TNF
7 response to wounding GO:0009611 9.92 CCR2 IL6 MYC
8 cellular response to interleukin-1 GO:0071347 9.92 CCL3 IL6 MYC
9 response to glucocorticoid GO:0051384 9.92 IL10 IL6 TNF
10 chemokine-mediated signaling pathway GO:0070098 9.91 CCL3 CCR2 CCR5
11 defense response to Gram-positive bacterium GO:0050830 9.91 B2M IL6 TNF
12 regulation of insulin secretion GO:0050796 9.91 IFNG IL1B TNF
13 cellular response to organic cyclic compound GO:0071407 9.91 CCL3 IL1B MYC TNF
14 neutrophil chemotaxis GO:0030593 9.9 CCL3 IFNG IL1B
15 response to cytokine GO:0034097 9.89 CD38 IL6 ITIH4
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.89 IL6 MYC TNF
17 positive regulation of inflammatory response GO:0050729 9.89 CCL3 CCR2 IL2
18 defense response to Gram-negative bacterium GO:0050829 9.88 B2M CD4 IL6
19 B cell differentiation GO:0030183 9.88 CD40LG CD79A IFNA1 IL10
20 MAPK cascade GO:0000165 9.87 CCL3 CCR5 CSF2 IL1B IL2 MYC
21 humoral immune response GO:0006959 9.86 IFNA1 IFNG IL6 TNF
22 inflammatory response GO:0006954 9.86 CCL3 CCR2 CCR5 CD40LG IL10 IL1B
23 positive regulation of interleukin-6 production GO:0032755 9.85 IL1B IL6 TNF
24 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.83 CSF2 IL1B TNF
25 protein kinase B signaling GO:0043491 9.83 CCL3 IL1B TNF
26 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 CSF2 IFNG IL2 IL6
27 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 CCL3 IL1B TNF
28 positive regulation of interferon-gamma production GO:0032729 9.8 CCR2 IL1B IL2 TNF
29 defense response to protozoan GO:0042832 9.79 IFNG IL10 IL6
30 positive regulation of nitric oxide biosynthetic process GO:0045429 9.78 IFNG IL1B IL6 TNF
31 negative regulation of growth of symbiont in host GO:0044130 9.77 IFNG IL10 TNF
32 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.77 IFNG IL1B TNF
33 B cell proliferation GO:0042100 9.76 CD40LG CD79A IFNA1 IL10
34 positive regulation of isotype switching to IgG isotypes GO:0048304 9.74 IFNG IL2
35 negative regulation of lipid storage GO:0010888 9.73 IL6 TNF
36 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.73 CD4 CSF2
37 response to cholesterol GO:0070723 9.73 CCL3 CCR5
38 signaling GO:0023052 9.73 CCL3 CCR5
39 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.73 IFNG IL1B
40 fusion of virus membrane with host plasma membrane GO:0019064 9.72 CCR5 CD4
41 endothelial cell apoptotic process GO:0072577 9.72 IL10 TNF
42 regulation of defense response to virus by host GO:0050691 9.72 IFNG IL1B
43 positive regulation of MHC class II biosynthetic process GO:0045348 9.72 IFNG IL10
44 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.72 IL10 IL1B